A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial

Antonio Gonzalez Martin*, Luisa Sanchez Lorenzo, Nicoletta Colombo, René Depont Christensen, Florian Heitz, Mihai Meirovitz, Frederic Selle, Toon Van Gorp, Nuria Alvarez, Javier Sanchez, Carmen Marqués

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

Fingerprint Dive into the research topics of 'A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences